BOOK BEFORE APRIL 20 & SAVE UP TO $400

May 22-24 2018 | Boston
www.treg-directed-therapies.com



Treg Summit 2018

Treg Directed Therapy for Autoimmune Disorders

Discover and produce stable, persistent and targeted Treg directed therapies that accelerate clinical development

In association with:

JDRF IMPROVING LIVES. CURING TYPE 1 DIABETES.

Stephane Boissel
Chief Executive Officer
TxCell

Jonathan Zalevsky
Senior Vice President Research & Chief Scientific Officer
Nektar Therapeutics

Jérémie Mariau
Chief Executive Officer
ILTOO Pharma

David Wraith
Director of the Institute of Immunology and Immunotherapy, **University of Birmingham** & Chief Scientific Officer
Apitope International NV

Simrit Parmar
Founder & Chief Medical Officer
Cellenkos

Stephen Miller
Professor, **Northwestern University Feinberg School of Medicine** & Co-founder, Consultant & Scientific Advisory Board Member
Cour Pharmaceutical

Tel: +1 415 735 3289 **Mail:** Info@hansonwade.com Treg in Autoimmunity @TregDTAD

hansonwade

Welcome to the only dedicated end-to-end Treg Directed Therapy for Autoimmune Disorders Summit

Explore the therapeutic strategies that increase the targeting specificity, persistence, and stability of Treg directed therapies.

As the scientific and commercial potential into autoimmune disorders steadily increases, exploit the targeting approach of Treg directed therapies to create first-in-class drugs for novel immunotherapeutic mechanisms to cure patients safely and effectively.

The **Treg Summit** is your opportunity to accelerate your immunology pipeline to the clinic by networking and learning with the expert leaders of the autoimmune community.

Hear the most advanced clinical case studies alongside innovative research methods to enhance the **specificity, persistence and targeting** of Treg directed therapies.

Access the most cutting edge data and learn about novel manufacturing developments to **future proof your therapeutic strategies.**

Join us in bringing together for the first time the expert autoimmune community and identify pioneering approaches to improve the functionality of Treg cells. Overcome the safety challenges faced with current standards of care by ensuring development of targeted immunotherapies.

Leave the **Treg Directed Therapy for Autoimmune Disorders Summit** fully equipped to progress your pipeline with a forward-looking plan for clinical translation.

What Hanson Wade's attendees have said about our cell therapy meetings

"The meeting has been well organised! Very interesting presentations with an agenda and topics being current. The conference has been well organized and perfectly timed"
ICON PLC

"A nice blend of academic, biotech, and pharmaceutical attendance in an environment that encourages cross-fertilization of ideas within cell therapy"
C4 Therapeutics

Top 5 Reasons Why This Summit Will Help Accelerate the Discovery and Development of Your Treg Pipeline:

1.

Enhance Treg Based Therapy with the Use of IL2
Utilize the stimulative capabilities of IL2 to increase differentiation, expansion and maintenance of Treg cells *in vivo*. Hear about novel clinical data from **Nektar** and **Amgen**.



2.

Achieve Antigen Specific Tolerance with Trafficking Approaches
Explore the use of CARs and TCRs to define the specificity of Treg cells, ensuring a precise targeting approach for your Treg directed therapeutic. Listen to novel gene editing approaches from **Casebia** and **TxCell**.

3.

Improve Targeting for Autoantigen Identification
Explore strategies to identify disease-specific autoantigens in order to enhance targeting to antigen-specific immunotherapies. Expand upon your Treg education and improve your understanding of targeting methods when knowledge of autoantigens lacks.



4.

Improve Methods to Increase Persistency of Stable Treg Cells
Join the discussion evaluating feasible methods to promote Treg stability to prevent their inherent ability to switch to pathogenic cells. Listen to talks from **Vedanta Bioscience** who explore the use of microbial drug products for the induction of immune tolerance.



5.

Explore Potential Future Breakthroughs in Treg Cell Manufacturing
Identify novel approaches and technologies which could lower cost for Treg manufacturing, which is critical to broader use of these therapies. Learn about new technologies which could aid Treg persistence and efficacy *in vivo*.



Your Expert Speaker Faculty

Chris Haqq
Chief Scientific Officer
Atara Biotherapeutics

Kevin Gorski
Principal Scientist, Clinical Biomarkers
Amgen

Nadia Tchao
Medical Director, Early Development, Inflammation
Amgen

David Wraith
Director of the Institute of Immunology and Immunotherapy, **University of Birmingham** & Chief Scientific Officer
Apitope International NV

Andrew Scharenberg
Chief Scientific Officer
Casebia Therapeutics

Simrit Parmar
Founder & Chief Medical Officer
Cellenkos

Robert Plenge
Vice President of Research & Early Development, Head of Immunology & Inflammation Thematic Center of Excellence,
Celgene

Niranjana Nagarajan
Principal Scientist, Biotherapeutics
Celgene

Stephen Miller
Professor at **Northwestern University Feinberg School of Medicine** & Co-founder, Consultant and member of the Scientific Advisory Board at **Cour Pharmaceutical**

Todd Brusko
Associate Professor, Diabetes Institute
University of Florida

Jérémie Mariau
Chief Executive Officer
ILTOO Pharma

Laurence Turka
CSO of **Rheos Medicines** & Deputy Director
Immune Tolerance Network

Jason Fontenot
Formerly the Head of Exploratory Research
Juno Therapeutics

Leonard Dragone
Senior Director of Translational Pharmacology & Experimental Medicine
Merck

Jonathan Zalevsky
Senior Vice President of Research & Chief Scientific Officer
Nektar Therapeutics

Aaron Winkler
Associate Research Fellow, Tolerance Lead
Pfizer

David Klatzmann
Director, Clinical Investigation Center for Biotherapy
Pitié-SalpêtrièreHospital

Jonathan Esensten
Co-Director, Clinical Regulatory T Cell Manufacturing Group & Medical Director
UCSF HICTF & GMP Facility

Leslie Kean
Associate Professor of Pediatrics
University of Washington

Annalisa D'Andrea Vice President and Global Head of Immunology & Inflammation Discovery
Roche

Rosa Bacchetta
Associate Professor of Research, Pediatrics, Stem Cell Transplantation
Stanford School of Medicine

Qizhi Tang
Professor and Director, UCSF Transplantation Research Lab, Department of Surgery
University of California, San Francisco

Dennis Kasper
Channing Professor of Medicine & Professor of Microbiology & Immunobiology, **Harvard Medical School** & Scientific Founder of **Symbiotix Biotherapies**

Stephane Boissel
Chief Executive Officer
TxCell

Pierre Heimendinger
Vice President of Process Development
TxCell

Rose Szabady
Senior Staff Scientist & Immunology Lead, Vedanta Bioscience
Vedanta Bioscience

David Hafler
Chairman, Department of Neurology and Professor of Immunology
Yale School of Medicine

Why Our Expert Speakers Get Involved in this Summit?

"I am looking forward to this opportunity of working alongside pharma and academics to accelerate the clinical development of effective and safe Treg directed therapies for our patients"

Leonard Dragone
Senior Director of Translational Pharmacology & Experimental Medicine
Merck

"It is an opportune time to discuss this therapy – scientific rationale for this therapy is strong based on preclinical data; we have some very early clinical experiences in this field now; we need to decide next steps"

Qizhi Tang
Professor and Director, UCSF Transplantation Research Lab, Department of Surgery
University of California, San Francisco

"The time for Ag-specific tolerance regulatory therapies for treatment of immune-mediated diseases including autoimmune disease, allergies and transplant has arrived. Exposure to up-to-date knowledge of how to most efficiently induce and utilize Ag-specific Tregs for autoimmune disease therapy will greatly accelerate translating these treatments into the clinic"

Stephen Miller
Professor at **Northwestern University Feinberg School of Medicine** & Co-founder, Consultant and member of the Scientific Advisory Board at **Cour Pharmaceutical**

"I am looking forward to hearing about the latest research on regulatory T-cell therapeutics, and interacting with the academic and industry researchers who are moving the field forwards"

Andrew Scharenberg
Chief Scientific Officer
Casebia Therapeutics

Conference Day One | Wednesday 23rd May 2018

Chris Haqq
Chief Scientific Officer
Atara Biotherapeutics

9.00 Chair's Opening Remarks

Define Tregs in Autoimmunity to Identify Molecular Change of Function

David Hafler
Chairman, Department of Neurology and Professor of Immunology
Yale School of Medicine

9.10 Regulatory T cells in Human Autoimmune Disease
- Identification of human Tregs
- Defects in Treg function in autoimmune disease
- Molecular mechanism for defects in Treg function

Therapeutic Strategies to Increase Targeting Specificity of Treg Cells

David Wraith
Director of the Institute of Immunology and Immunotherapy, **University of Birmingham** & Chief Scientific Officer **Apitope International NV**

9.40 Induction of Regulatory T Cells by Antigen-Specific Immunotherapy
- Rationale for antigen-specific immunotherapy
- Mechanism of antigen-specific immunotherapy with peptide antigens
- Nature of regulatory T cells induced by antigen-specific immunotherapy
- Pre-clinical and of antigen-specific immunotherapy in autoimmune diseases

10.10 Morning Refreshments and Speed Networking

Explore Different Therapies to Modulate Treg Function

Stephen Miller
Professor at **Northwestern University Feinberg School of Medicine** & Co-founder, Consultant and member of the Scientific Advisory Board at **Cour Pharmaceutical**

11.10 A Nanoparticle-based Negative T Cell Vaccine for Treg Therapy of Autoimmune Disease
- Demonstrate the utility of i.v. infusion of antigen-encapsulating biodegradable PLG nanoparticles [PLG(Ag)] for tolerogenic treatment of mouse models of multiple sclerosis and type 1 diabetes
- Demonstrate that PLG(Ag) nanoparticles target MARCO-expressing tolerogenic antigen presenting cells in the splenic marginal zone and liver
- Demonstrate the ability to tolerize both naïve and activated autoreactive CD4 and CD8 T cells
- Demonstrate the critical role of antigen-specific Tregs in tolerance induction and maintenance via regulating autoimmune effector T cell trafficking and effector function
- Explain the pathway for clinical translation of the technology for clinical testing in celiac disease

Dennis Kasper
Channing Professor of Medicine and Professor of Microbiology and Immunobiology **Harvard Medical School** & Scientific Founder of **Symbiotix Biotherapies**

11.40 The Microbiome as a Source of Molecules able to Induce Regulatory T cells
- The microbiome is a potential source of molecules that can modulate immune cells - including regulatory T cells
- Baceroides fragilis is an important part of the gut microbiome and has a polysaccharide capsule (PSA) that is highly immunomodulatory
- PSA can induce regulatory T cells at the site of inflammation and these cells make IL-10 which shuts down inflammatory cytokine production
- PSA can be given orally and stimulates on both the innate and adaptive immune system to induce IL-10 producing T regulatory cells

12.10 Lunch and Networking

Methods to Increase the Persistence of Stable Treg Cells

Rose Szabady
Senior Staff Scientist & Immunology Lead, Vedanta Bioscience
Vedanta Bioscience

13.10 Development of Defined Microbial Drug Products for Induction of Immune Tolerance
- Rational design of bacterial consortia based on translational medicine data
- Optimization of bacterial consortia via bioinformatics analyses
- Mechanisms of bacterial consortia-mediated immune tolerance induction

David Klatzmann
Director, Clinical Investigation Center for Biotherapy
Pitié-SalpêtrièreHospital

13.40 IL-2 Sufficient Super-Tregs with Improved Survival and Suppressive Activity

- IL-2 supports Tregs' development, survival and suppressive activity, but Tregs cannot produce IL-2
- Tregs for clinical use are produced by culture in IL-2 rich medium and likely suffer when injected in relatively IL-2 deprived patients
- We gene-modified Tregs such as they produce their own IL-2, and express additional features such as CAR
- Such Tregs are self-sufficient in vitro and in vivo and have much improved suppressive activity
- Thus, autocrine production of IL-2 dramatically improves the therapeutic potential of Tregs and could advantageously be introduced in CAR Treg design

Leonard Dragone
Senior Director of Translational Pharmacology & Experimental Medicine
Merck

Rose Szabady
Senior Staff Scientist & Immunology Lead, Vedanta Bioscience
Vedanta Bioscience

Laurence Turka
Chief Scientific Officer of **Rheos Medicines** & Deputy Director
Immune Tolerance Network

Simrit Parmar
Founder & Chief Medical Officer
Cellenkos

Jason Fontenot
Formerly the Head of Exploratory Research
Juno Therapeutics

14.10 Panel Discussion: Evaluate Feasible Methods to Promote the Stability of Treg Cells to Prevent a Pathogenic Switch to T Effector Cells

- Discuss concerns regarding instability of Tregs and their inherent ability to switch to pathologic cells
- Identify methods to maintain the cells regulatory function
- Ensure genetic modification of Treg cells to promote stability is feasible to maintain access and delivery to patients

15.10 Afternoon Refreshments

Enhance Treg-based Therapy with the Use of IL2

Jonathan Zalevsky
Senior Vice President of Research & Chief Scientific Officer
Nektar Therapeutics

15.40 NKTR-358: An IL-2 Pathway Agonist that Selectively Expands and Activates Regulatory T Cells for the Treatment of Allergy and Autoimmune Disease

- NKTR-358 was created from Nektar's polymer chemistry technology and extensive experience with the IL-2 pathway -it is currently in Phase 1 clinical studies
- NKTR-358 selectively expands and activates Tregs with minimal activity on NK cells and Tcons
- NKTR-358 demonstrates efficacy in multiple preclinical models of disease, contact hypersensitivity, and oral tolerance models of food allergy

Nadia Tchao
Medical Director, Early Development, Inflammation
Amgen

16.10 AMG 592: An Investigational IL-2 Mutein That Induces Highly Selective Expansion of Regulatory T Cells

- AMG 592 is an investigational IL-2 mutein that selectively expands T regulatory cells with minimal expansion of NK cell and T conventional cells
- AMG 592 demonstrates improved Treg selectivity, reduced production of inflammatory cytokines and decreased systemic markers of inflammation in non- human primates compared to Proleukin
- AMG 592 causes a dose-dependent expansion of Tregs in healthy subjects given a single dose and was safe and well tolerated
- AMG 592 is being developed for the treatment of autoimmune diseases and has broad therapeutic potential across multiple indications in which immune tolerance is impaired

Annalisa D'Andrea, Vice President and Global Head of Immunology & Inflammation Discovery
Roche

16.40 A Novel IgG-IL2 Mutein to Selectively Activate T Regulatory Cells

- Explore how the therapeutic index for recombinant IL-2 in autoimmune conditions appears narrow due to dose limiting side effects, and the short half-life of the molecule requires frequent dosing
- Thus, a new therapeutic approach that re-establishes the natural regulatory T cell (Treg) mediated dominant immune tolerance and severely minimizes any potential stimulatory effects on CD4+ memory T effector cells would greatly enhance the ability to treat patients with autoimmune diseases such as type 1 diabetes, systemic lupus erythematosus, and IBD
- Roche's RO7049665 is an IgG-IL2 fusion protein that preferentially activate human and non-human Tregs with little or no effect on human CD4+memory T effector cells, tipping the balance toward a higher Treg:Teff ratio and reduce the autoimmune response
- In addition, IgG-IL2 is long-lived, allowing convenient dosing schedules, and devoid of effector functions, reducing potential side effects and impairment of efficacy

Jérémie Mariau, Chief Executive Officer
ILTOO Pharma

17.10 Plain is Beautiful (and Enough)

- IL-2 at low doses stimulates Tregs and blocks Th17 and Tfh differentiation
- IL-2 has a uniquely broad therapeutic scope in the field of autoimmune and inflammatory diseases
- ILTOO Pharma is the pioneer of plain IL-2 development
- Clinical trial results support this potential and show a suitable therapeutic window for plain IL-2
- The tremendously different clinical settings for IL-2 - from acute treatment of flares to chronic maintenance of an homeostatic balance and in various tissues - already call for multiple usages of IL-2

Chris Haqq Chief Scientific Officer
Atara Biotherapeutics

17.40 Chair's Closing Remarks

17.45 End of Day 1

"Well organized and intimate with good opportunities for networking"

Past CVI Summit Attendee, NUI Galway

Conference Day Two | Thursday 24th May 2018

Chris Haqq
Chief Scientific Officer
Atara Biotherapeutics

9.00 Chair's Opening Remarks

Identify Optimal Treg Populations With Increased Functional Capacity

Rosa Bacchetta
Associate Professor of Research, Pediatrics, Stem Cell Transplantation
Stanford School of Medicine

9.10 LV- Mediated Gene Transfer to Generate T-regulatory Cells Suitable for Immunotherapy

- Discuss the lentiviral vector (LV)-based strategy to ectopically express high levels of FOXP3 in CD4+ effector T cells which consistently results in stable suppressive cells that are as potent as FOXP3+ Tregs and can be generated in large numbers
- Explore how the conversion of effector T cells into FOXP3+ Tregs upon LV-mediated gene transfer of wild-type FOXP3 was also obtained in CD4+ T cells from IPEX patients, in whom Treg are functionally impaired because of mutations of the FOXP3 gene
- Identify how LV-mediated gene transfer of human IL-10 into conventional CD4+ T cells leads to the differentiation of homogeneous populations of Tr1-like cells displaying potent suppressive functions both in vitro and in vivo
- Discuss the advantages and challenges in the use of LV-FOXP3+ Tregs or LV-IL-10 Tr1 cell-based therapy for different indications

Qizhi Tang
Professor and Director, UCSF Transplantation Research Lab, Department of Surgery
University of California, San Francisco

9.40 Clinical Trials of Treg Cell Therapy in Transplantation

- Discuss an overview of the UCSF Treg cell therapy program
- Outline the up-to-date work in progress in various clinical trials at UCSF
- Explore the future development in this space

10.10 Morning Refreshments

Explore The Limitations Translating Outcomes from Animal Models into Human Disease

Leslie Kean
Associate Professor of Pediatrics
University of Washington

11.10 Building an Optimal Treg Product: Lessons from NHP Studies

- There is a critical unmet need for large animal model in Treg studies
- NHP can model both the benefits and challenges of Treg-based therapies
- We have identified a regimen that effectively prolongs Treg persistence, but there remain challenges with phenotypic stability of ex-vivo expanded nTregs in NHP

Chris Haqq
Chief Scientific Officer
Atara Biotherapeutics

Stephen Miller
Professor at **Northwestern University Feinberg School of Medicine** & Co-founder, Consultant and member of the Scientific Advisory Board at **Cour Pharmaceutical**

David Wraith
Director of the Institute of Immunology and Immunotherapy, **University of Birmingham** & Chief Scientific Officer **Apitope International NV**

Leslie Kean
Associate Professor of Pediatrics
University of Washington

11.40 Panel Discussion: Animal Models and Beyond into the Clinic: Translating a Proof of Concept in Autoimmune Therapies

- Discuss the most appropriate model to use to ensure reliable data is collected to move into clinic
- Address the challenge of turning off an already activated immune system and re-establishing tolerance and how to model this therapy in model organisms
- Consider challenges of immune-compromised humanised mice for use as proof of concept
- Discuss the challenge of using Treg directed therapies alongside current therapeutics used in humans
- Explore the clinical landscape involved in moving these therapies from animal to humans

12.10 Lunch and Networking

Discussion Session to Support the Discovery and Clinical Development of Treg Directed Therapies

13.10 Round table Discussion

1 Identify Key Manufacturing Considerations to Ensure Feasible Large Scale Clinical Trials

- Identify what purity standards should be used in preclinical trials
- Discuss potential assays to assess functional aspect of cells
- Identify mechanistic assays that should be induced in tolerance based clinical trials
- How to standardize the expansion of Treg populations

Pierre Heimendinger
Vice President of Process Development
TxCell

2 Outline the Benefits of Biomarkers in Autoimmune Disease and Methods to Explore Them Clinically

- Discuss the use of biomarkers in antigen specific autoimmune diseases
- Identification of biomarkers to predict onset of disease and allow early intervention
- Explore clinical approaches to identify specific biomarkers

Kevin Gorski
Principal Scientist, Clinical Biomarkers
Amgen

14.10 Afternoon Refreshments

Comparison of Trafficking Approaches to Achieve Antigen Specific Tolerance

Andrew Scharenberg
Chief Scientific Officer
Casebia Therapeutics

14.40 Engineering Regulatory T-cells for Inflammatory Disorders

- Describe a gene editing approach which enforces FOXP3 expression in CD4 T-cells
- Explore the manufacturing protocol compatible with translational scale up
- Identify the optimal protocol which allows the generation of engineered autologous CD4 T-cell populations that resemble natural regulatory T-cells in surface phenotype, transcriptome and suppressive activity

Todd Brusko
Associate Professor, Diabetes Institute
University of Florida

15.10 Therapeutic Applications of Cord Blood-Derived Tregs for the Treatment of Type 1 Diabetes

- Comparison of cord blood-derived Tregs to adult peripheral blood Tregs
- Mechanisms for generating antigen-specific Tregs by TCR gene transfer
- Biomaterial modifications of Tregs as drug delivery vehicles

Stephane Boissel
Chief Executive Officer
TxCell

15.40 Engineered Tregs for Autoimmunity, Inflammation and Transplantation

- TxCell develops engineered Tregs targeting autoimmune and inflammatory diseases as well as transplantation-related inflammatory disorders
- TxCell's lead CAR-Treg program targets HLA-A2, a common mismatch antigen in transplantation. This program is in development for the prevention of chronic rejection after solid organ transplantation. It is on track to enter clinical studies by end 2018 (IND or equivalent filing) following positive results in preclinical models of graft rejection
- TxCell has completed a viable manufacturing process for its HLA-A2 CAR-Treg cells in view of entering the clinic

Chris Haqq
Chief Scientific Officer
Atara Biotherapeutics

16.10 Encouraging Safety and Efficacy From Pioneering T-Cell Immunotherapy Clinical Studies in Autoimmune Disease

- Epstein-Barr Virus (EBV) is associated with a wide range of cancers, as well as certain autoimmune conditions such as multiple sclerosis (MS). Atara's off-the-shelf (allogenic) ATA188 and autologous ATA190 T-cell immunotherapies have the potential to precisely recognize and eliminate EBV-infected B-cells and plasma cells in the central nervous system that may catalyze autoimmune responses and MS pathophysiology
- Recent results from the first autologous T-cell immunotherapy study in patients with progressive MS showed that ATA190 led to encouraging clinical improvements in MS symptoms. Six of ten progressive MS patients experienced clinical improvements, which were first observed 2-14 weeks after the initial infusion. Three patients in the study improved their Expanded Disability Status Scale (EDSS) score. ATA190 was well-tolerated, and no significant treatment-related adverse events were observed in the study
- Atara recently initiated a global Phase 1 off-the-shelf ATA188 clinical study expected to enroll a total of 60 MS patients across the U.S., Australia and Europe. ATA188 may allow for a more consistent reactivity against target EBV antigens, which correlated with clinical improvements in the previous autologous ATA190 Phase 1 study

Aaron Winkler
Associate Research Fellow, Tolerance Lead
Pfizer

Andrew Scharenberg
Chief Scientific Officer
Casebia Therapeutics

16.40 Panel Discussion : The Advantages and Disadvantages of Using Different Moieties to Target Treg Cells

- Discuss the benefits and challenges of using TCRs to target Treg cells
- Identify the limitations in identifying antigen targets for CAR-Treg cells
- Is adoptive cell therapy utilizing ex vivo expanded polyclonal Tregs via non-specific TCR stimulation sufficient?

JDRF Patient Advocate

17.10 Living with Type 1 Diabetes

A representative from JDRF, the world's largest private non-governmental funder of type 1 diabetes (T1D) research, will share their personal experience of living with type 1 diabetes. This talk will also outline the work of JDRF in their efforts to cure, treat and prevent T1D by funding research, advocating for government support of research and new therapies, ensuring new therapies come to market and connecting and engaging the T1D community.

Chris Haqq
Chief Scientific Officer
Atara Biotherapeutics

17.30 Chair's Closing Remarks

17.35 End of Day 2

"Best focused meeting on CAR and TCR development, from bench to clinic"

Past CVI Summit Attendee, Pfizer

Pre-Conference Workshop Day | Tuesday 22nd May 2018

Workshop A

An In-depth Exploration of Treg Cell Heterogeneity

9:00am - 12:00pm

This workshop explores the heterogeneity of Treg cells which ensures that the immune responses are regulated and tolerance is maintained. Tregs are highly heterogeneous populations however the understanding of the cellular and molecular pathways are limited. When Tregs lose their phenotype and suppressive functions they become pathogenic. Attend this workshop to improve your understanding on the significance of Treg heterogeneity in peripheral blood and tissues and explore their role in maintaining peripheral immune tolerance.

Attendees will learn:

- Outline the clinical landscape surrounding the heterogeneity of Treg subsets
- Explore tissue specific Treg cells and how to target specific subsets

Workshop Leader

Robert Plenge, Vice President of Research & Early Development, Head of Immunology & Inflammation, Thematic Center of Excellence, **Celgene**

Robert is Vice President, Translational Development, Research & Early Development and Head of the Inflammation & Immunology Thematic Center of Excellence (TCoE) Unit at Celgene. He is responsible for the strategic vision, implementation, and partnership of novel therapies for immune, inflammatory, and fibrotic disorders.

Prior to joining Celgene in May 2017, Robert was Vice President and Head of Translational Medicine at Merck & Company. His team was responsible for translating basic science into therapeutic trials across all therapeutic areas, with areas of emphasis such as: identifying novel targets and pathways based on causal human biology (e.g., human genetics, pharmacological perturbations); deploying molecular and imaging biomarkers into clinical trials; and conducting first-in-human studies, clinical proof-of-concept trials, and additional Phase I/IIa studies to support registration.

Workshop Leader

Niranjana Nagarajan, Principal Scientist, Biotherapeutics, **Celgene**

Niranjana is a Principal Scientist in Biotherapeutics, at Celgene, working on the next generation of Treg-modifying therapies for autoimmune and inflammatory diseases. She was one of the early scientists at Delinia Biosciences, and came to Celgene as part of Celgene's acquisition of Delinia in 2017. Prior to Celgene, she worked on early and late stage allogeneic CAR T cells at Pfizer, identifying and validating targets, developing new targeting molecules, and conducting preclinical research on cell therapy for oncology.

"I can't speak highly enough about this conference. This conference allowed me to keep informed of the latest research and development on T cell therapies. I was also able to network with some of the leaders in T cell immunotherapies from both academia and the industry."

Past CVI Attendee, MSKCCs

Workshop B

New Approaches to Improving Cell Yield, Process Efficiency, and Therapeutic Potency in Clinical Regulatory T Cell Manufacturing Processes

1:00pm - 4:00pm

Regulatory T cells (Tregs) are currently in clinical trials for a variety of indications, including graft versus host disease, autoimmune diseases, and induction of tolerance after solid organ transplant. A variety of new and old technologies and approaches are in active development to improve yields of Treg isolations, increase fold expansion, bring open processes into closed systems, target cells to specific tissues, and genetically modify cells to improve activity. Some of these approaches and technologies could lower cost for Treg manufacturing, which is critical to broader use of these therapies. Attend this manufacturing master class to gain an in-depth understanding of the current approaches and potential future breakthroughs in regulatory T cell manufacturing.

Attendees will learn:

- Strategies for improving Treg yields at lower costs
- Considerations for manufacturing processes and release criteria to ensure safety
- Current state of new technologies, including synthetic biology approaches, which could improve Treg persistence and efficacy *in vivo*

Workshop Leader

Pierre Heimendinger, Vice President of Process Development, **TxCell**

Pierre has over 30 years of experience in biotechnology, immunotherapy, vaccines, plasma-derived medicinal products and viral vectors. Since he joined TxCell in late 2015, Pierre has been instrumental in developing TxCell's first CAR-Treg manufacturing process. Before joining TxCell, Pierre held a senior position at Transgene SA where he led the pharmaceutical development team and was responsible for the development of new processes, analytical methods and technology transfer. He started his career at Sanofi Pasteur, then at Mérieux and Octapharma. Pierre has a doctor of pharmacy degree complemented by a postgraduate in cellular and genetic toxicology from the University of Paris VII.

Workshop Leader

Jonathan Esensten, Co-Director, Clinical Regulatory T Cell Manufacturing Group & Medical Director, **UCSF HICTF & GMP Facility**

Jonathan Esensten MD, PhD is a Leukemia and Lymphoma Society Fellow in the laboratory of Dr. Wendell Lim. His research is focused the development of synthetic and chemical biology approaches for T cell therapeutics. He is co-director of the clinical Regulatory T Cell Manufacturing Group. He is also Medical Director of the UCSF HICTF and GMP Facility, which manufactures regulatory T cell products for clinical trials, among other cell therapy activities. He completed residency in clinical pathology and fellowship in transfusion medicine and blood banking at UCSF.

> "I think that the meeting is a great place for folks to come together and talk about real issues. It is also a great place to network with future and previous colleagues doing novel things in the cell and gene therapy space."
>
> **Past CVI Summit Attendee, Unum Therapeutics**

PARTNERS

Industry Partner

TxCell is a French biotechnology company that develops cellular immunotherapies based on regulatory T lymphocytes (Tregs) for the treatment of severe inflammatory and autoimmune diseases with high unmet medical needs. More precisely, TxCell develops engineered antigen-specific Tregs, where the antigen specificity is brought by a Chimeric Antigen Receptor (CAR) (CAR-Treg cells). TxCell aims at shortly bringing this innovation for the first time to human testing, with a first IND filing (or equivalent) by end 2018.

www.txcell.com

WHY PARTNER

The Treg Directed Therapy for Autoimmune Disorders Summit is the only dedicated meeting focused on the challenges faced by pharma, biotech & academia in their race to clinical translation of Treg directed therapies. Autoimmunity is seen as the biggest unmet medical need on a global scale and following on from the excitement from the **immune revolution**, inflammatory autoimmune conditions are considered the next therapeutic area where immunotherapy can really make a significant difference.

Continuing their momentum to move Treg directed therapies into the clinic, drug developers are actively seeking external expertise across **biomarker identification, potency and efficacy testing, efficient cell processing, commercially viable manufacture and reliable clinical research.** Can you support the development of the next generation of immunotherapies?

Partnering with the **Treg Directed Therapy for Autoimmune Disorders Summit** will ensure you capitalize on the market early, cement your position as an industry leader and support the rate of discovery and clinical development of targeted, safe and effective Treg directed therapies.

TYPICAL ATTENDANCE SENIORITY



ESTIMATED ATTENDANCE BY INDUSTRY TYPE



*Based on market research and previous events' statistics

GET INVOLVED

Jennifer Mackay
Partnerships Director
Tel: +1 415 735 3289
Email: sponsor@hansonwade.com

READY TO REGISTER?

3 EASY WAYS TO BOOK

www.treg-directed-therapy.com/take-part

Tel: +1 415 735 3289

Email: register@hansonwade.com

1. **Learn** from the leading experts in the autoimmune community and join the discussion to overcome key challenges limiting this space.
2. **Hear** the most successful clinical case studies and novel therapeutic strategies to increase the efficacy of your Treg directed therapy.
3. **Network** with pioneering leaders and experts of the autoimmune community and take this opportunity to create collaborative partnerships for future clinical prospects

Team Discounts*

- **10% discount – 3 delegates**
- **15% discount – 4 delegates**
- **20% discount – 5 or more delegates**

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Contact: register@hansonwade.com

SECURE YOUR PLACE

Industry Pricing	Register & Pay by Friday April 20	Standard
Conference + 2 Workshops	$3397 **(save $400)**	$3797 **(save $200)**
Conference + 1 Workshop	$2898 **(save $400)**	$3298 **(save $100)**
Conference Only	$2399 **(save $400)**	$2799
Workshops (Each)	$599	

Academic Pricing	Register & Pay by Friday April 20	Standard
Conference + 2 Workshops	$2597 **(save $200)**	$2797 **(save $200)**
Conference + 1 Workshop	$2198 **(save $200)**	$2398 **(save $100)**
Conference Only	$1799 **(save $200)**	$1999
Workshops (Each)	$499	

VENUE

Westin Boston Waterfront
425 Summer Street, Boston,
MA, 02210, United States

For further information or assistance, please visit wwww.westinbostonwaterfront.com

Code: 9769